Myeloma drugs tested for home use: could cut hospital stays
NCT ID NCT05972135
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether two drugs, teclistamab and talquetamab, can be given safely in an outpatient setting for people with multiple myeloma. The study will enroll 100 participants who have already tried other treatments. The main goal is to see how often side effects like cytokine release syndrome (CRS) occur when preventive medicines are used, with the hope of making treatment more convenient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teclistamab or Talquetamab (drugs given as shots under the skin)
What this could lead to
If successful, this could allow multiple myeloma patients to receive these powerful drugs safely as outpatients, reducing time in the hospital.
What could go wrong
This is a small, early-phase study (100 people) focused on safety and side effects, not yet on cure. Side effects like cytokine release syndrome (CRS) are still a risk, even with preventive medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Oncology Associates
RECRUITINGTucson, Arizona, 85711, United States
-
Blue Ridge Cancer Center
RECRUITINGRoanoke, Virginia, 24014, United States
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Florida Cancer Specialists
WITHDRAWNLake Mary, Florida, 32746, United States
-
Maryland Oncology Hematology
RECRUITINGColumbia, Maryland, 21044, United States
-
Medical Oncology Hematology Consultants
RECRUITINGNewark, Delaware, 19713, United States
-
Minnesota Oncology Hematology
RECRUITINGMinneapolis, Minnesota, 55404, United States
-
Oncology Associates of Oregon
RECRUITINGEugene, Oregon, 97401, United States
-
Oncology Hematology Care
RECRUITINGCincinnati, Ohio, 45242, United States
-
Rocky Mountain Cancer Center
RECRUITINGDenver, Colorado, 80218, United States
-
Texas Oncology
RECRUITINGAustin, Texas, 78705, United States
-
Texas Oncology - Northeast Texas
RECRUITINGTyler, Texas, 75702, United States
-
Texas Oncology - San Antonio
RECRUITINGSan Antonio, Texas, 78240, United States
-
TriStar Bone Marrow Transplant
RECRUITINGNashville, Tennessee, 37203, United States
-
Vanderbilt- Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
-
Virginia Oncology Associates
RECRUITINGElizabeth City, North Carolina, 27909, United States